Main distributor to Brazil and Latin America for analytical reference substances  |  Welcome! Olá! Hola! Español  |  +1.919.484.7555
You are here: Home /USA, USFDA /US FDA consults drug companies on best approaches to REMS assessment

US FDA consults drug companies on best approaches to REMS assessment

by JMC on May 23, 2012

The US Food and Drug Administration is seeking to improve how pharmaceutical companies assess whether their approved risk evaluation and mitigation strategy (REMS) for a marketed drug is achieving its intended goal of informing and educating patients and healthcare providers about the risks of the drug1

Click here to read more…

Previous post:

Next post: